Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-up

Giuseppe Cianchini, Francesca Lupi, Cinzia Masini, Rosamaria Corona, Pietro Puddu, Ornella De Pità

Research output: Contribution to journalArticle

Abstract

Background: Rituximab induces depletion of B cells and has shown efficacy in antibody-mediated autoimmune disorders. In studies on small series of patients with pemphigus, rituximab administration results in significant improvement. However, differences in inclusion criteria, treatment protocols, and follow-up make it difficult to derive uniform conclusions. Objectives: We sought to test the efficacy and tolerability of rituximab as adjuvant therapy to corticosteroids in the treatment of pemphigus. Methods: In all, 42 patients with pemphigus were treated with rituximab and followed up for up to 5 years. No additional immunosuppressive agents were used. Steroids were rapidly tapered. Outcomes were the proportion of patients who achieved a complete response on or off therapy, the rate of discontinuation of corticosteroid within 6 months, length of remission, time to relapses, and occurrence of adverse events. Results: In all, 36 of 42 patients (86%; 95% confidence interval 75%-96%) achieved a complete response on or off therapy and discontinued steroids within 6 months from induction therapy. Six patients had a complete response off therapy with an additional infusion of rituximab 6 months after initial treatment. Twenty patients experienced a total of 34 relapses; the time to relapse was 8 to 64 months. Every relapse was treated with rituximab (500 mg) without corticosteroids, which induced a new complete response. No serious adverse events were observed. Limitations: Lack of a control group is a limitation. Conclusions: Rituximab therapy induces prolonged clinical remission in patients with pemphigus. Coadministration of other immunosuppressive agents is not necessary. Relapses can be managed with additional infusions administered on demand.

Original languageEnglish
Pages (from-to)617-622
Number of pages6
JournalJournal of the American Academy of Dermatology
Volume67
Issue number4
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Pemphigus
Observational Studies
Recurrence
Adrenal Cortex Hormones
Therapeutics
Immunosuppressive Agents
Steroids
Rituximab
Clinical Protocols
B-Lymphocytes
Confidence Intervals
Control Groups
Antibodies

Keywords

  • adverse events
  • autoimmune bullous diseases
  • B cell-depleting treatment
  • immunosuppressive treatment
  • monoclonal antibodies
  • pemphigus
  • relapses
  • rituximab
  • therapy

ASJC Scopus subject areas

  • Dermatology

Cite this

Therapy with rituximab for autoimmune pemphigus : Results from a single-center observational study on 42 cases with long-term follow-up. / Cianchini, Giuseppe; Lupi, Francesca; Masini, Cinzia; Corona, Rosamaria; Puddu, Pietro; De Pità, Ornella.

In: Journal of the American Academy of Dermatology, Vol. 67, No. 4, 10.2012, p. 617-622.

Research output: Contribution to journalArticle

Cianchini, Giuseppe ; Lupi, Francesca ; Masini, Cinzia ; Corona, Rosamaria ; Puddu, Pietro ; De Pità, Ornella. / Therapy with rituximab for autoimmune pemphigus : Results from a single-center observational study on 42 cases with long-term follow-up. In: Journal of the American Academy of Dermatology. 2012 ; Vol. 67, No. 4. pp. 617-622.
@article{fbce72b9981b4554b806196993ecaeae,
title = "Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-up",
abstract = "Background: Rituximab induces depletion of B cells and has shown efficacy in antibody-mediated autoimmune disorders. In studies on small series of patients with pemphigus, rituximab administration results in significant improvement. However, differences in inclusion criteria, treatment protocols, and follow-up make it difficult to derive uniform conclusions. Objectives: We sought to test the efficacy and tolerability of rituximab as adjuvant therapy to corticosteroids in the treatment of pemphigus. Methods: In all, 42 patients with pemphigus were treated with rituximab and followed up for up to 5 years. No additional immunosuppressive agents were used. Steroids were rapidly tapered. Outcomes were the proportion of patients who achieved a complete response on or off therapy, the rate of discontinuation of corticosteroid within 6 months, length of remission, time to relapses, and occurrence of adverse events. Results: In all, 36 of 42 patients (86{\%}; 95{\%} confidence interval 75{\%}-96{\%}) achieved a complete response on or off therapy and discontinued steroids within 6 months from induction therapy. Six patients had a complete response off therapy with an additional infusion of rituximab 6 months after initial treatment. Twenty patients experienced a total of 34 relapses; the time to relapse was 8 to 64 months. Every relapse was treated with rituximab (500 mg) without corticosteroids, which induced a new complete response. No serious adverse events were observed. Limitations: Lack of a control group is a limitation. Conclusions: Rituximab therapy induces prolonged clinical remission in patients with pemphigus. Coadministration of other immunosuppressive agents is not necessary. Relapses can be managed with additional infusions administered on demand.",
keywords = "adverse events, autoimmune bullous diseases, B cell-depleting treatment, immunosuppressive treatment, monoclonal antibodies, pemphigus, relapses, rituximab, therapy",
author = "Giuseppe Cianchini and Francesca Lupi and Cinzia Masini and Rosamaria Corona and Pietro Puddu and {De Pit{\`a}}, Ornella",
year = "2012",
month = "10",
doi = "10.1016/j.jaad.2011.11.007",
language = "English",
volume = "67",
pages = "617--622",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Therapy with rituximab for autoimmune pemphigus

T2 - Results from a single-center observational study on 42 cases with long-term follow-up

AU - Cianchini, Giuseppe

AU - Lupi, Francesca

AU - Masini, Cinzia

AU - Corona, Rosamaria

AU - Puddu, Pietro

AU - De Pità, Ornella

PY - 2012/10

Y1 - 2012/10

N2 - Background: Rituximab induces depletion of B cells and has shown efficacy in antibody-mediated autoimmune disorders. In studies on small series of patients with pemphigus, rituximab administration results in significant improvement. However, differences in inclusion criteria, treatment protocols, and follow-up make it difficult to derive uniform conclusions. Objectives: We sought to test the efficacy and tolerability of rituximab as adjuvant therapy to corticosteroids in the treatment of pemphigus. Methods: In all, 42 patients with pemphigus were treated with rituximab and followed up for up to 5 years. No additional immunosuppressive agents were used. Steroids were rapidly tapered. Outcomes were the proportion of patients who achieved a complete response on or off therapy, the rate of discontinuation of corticosteroid within 6 months, length of remission, time to relapses, and occurrence of adverse events. Results: In all, 36 of 42 patients (86%; 95% confidence interval 75%-96%) achieved a complete response on or off therapy and discontinued steroids within 6 months from induction therapy. Six patients had a complete response off therapy with an additional infusion of rituximab 6 months after initial treatment. Twenty patients experienced a total of 34 relapses; the time to relapse was 8 to 64 months. Every relapse was treated with rituximab (500 mg) without corticosteroids, which induced a new complete response. No serious adverse events were observed. Limitations: Lack of a control group is a limitation. Conclusions: Rituximab therapy induces prolonged clinical remission in patients with pemphigus. Coadministration of other immunosuppressive agents is not necessary. Relapses can be managed with additional infusions administered on demand.

AB - Background: Rituximab induces depletion of B cells and has shown efficacy in antibody-mediated autoimmune disorders. In studies on small series of patients with pemphigus, rituximab administration results in significant improvement. However, differences in inclusion criteria, treatment protocols, and follow-up make it difficult to derive uniform conclusions. Objectives: We sought to test the efficacy and tolerability of rituximab as adjuvant therapy to corticosteroids in the treatment of pemphigus. Methods: In all, 42 patients with pemphigus were treated with rituximab and followed up for up to 5 years. No additional immunosuppressive agents were used. Steroids were rapidly tapered. Outcomes were the proportion of patients who achieved a complete response on or off therapy, the rate of discontinuation of corticosteroid within 6 months, length of remission, time to relapses, and occurrence of adverse events. Results: In all, 36 of 42 patients (86%; 95% confidence interval 75%-96%) achieved a complete response on or off therapy and discontinued steroids within 6 months from induction therapy. Six patients had a complete response off therapy with an additional infusion of rituximab 6 months after initial treatment. Twenty patients experienced a total of 34 relapses; the time to relapse was 8 to 64 months. Every relapse was treated with rituximab (500 mg) without corticosteroids, which induced a new complete response. No serious adverse events were observed. Limitations: Lack of a control group is a limitation. Conclusions: Rituximab therapy induces prolonged clinical remission in patients with pemphigus. Coadministration of other immunosuppressive agents is not necessary. Relapses can be managed with additional infusions administered on demand.

KW - adverse events

KW - autoimmune bullous diseases

KW - B cell-depleting treatment

KW - immunosuppressive treatment

KW - monoclonal antibodies

KW - pemphigus

KW - relapses

KW - rituximab

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84859980675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859980675&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2011.11.007

DO - 10.1016/j.jaad.2011.11.007

M3 - Article

C2 - 22243765

AN - SCOPUS:84859980675

VL - 67

SP - 617

EP - 622

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 4

ER -